Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091660 · ClinicalTrials.gov registry record · Phase 3
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
A Phase 3 study of Stage 0 Bladder Urothelial Carcinoma and Stage 0is Bladder Urothelial Carcinoma, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT03091660 is a Phase 3 study of Stage 0 Bladder Urothelial Carcinoma and Stage 0is Bladder Urothelial Carcinoma that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 1,000 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT03091660, a Phase 3 study of Stage 0 Bladder Urothelial Carcinoma and Stage 0is Bladder Urothelial Carcinoma, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL BCG Solution
- BIOLOGICAL BCG Tokyo-172 Strain Solution
- BIOLOGICAL BCG Tokyo-172 Strain Vaccine
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Institute Palo Alto - Palo Alto
- Kaiser Permanente-South Sacramento - Sacramento
- UCSF Medical Center-Mission Bay - San Francisco
- Kaiser Permanente-Vallejo - Vallejo
- Kaiser Permanente-Walnut Creek - Walnut Creek
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Connecticut
- Smilow Cancer Center/Yale-New Haven Hospital - New Haven
- Yale University - New Haven
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
- George Washington University Medical Center - Washington D.C.
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03091660
The ClinicalTrials.gov registry entry for NCT03091660 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage 0 Bladder Urothelial Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03091660 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03091660 about?
NCT03091660 is a clinical study titled "S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer". This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infe...
What is the current status of trial NCT03091660?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2017-02-24. Estimated completion is 2026-06-15.
What conditions does trial NCT03091660 study?
This clinical trial studies the following conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma.
What interventions are being tested in trial NCT03091660?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), BCG Solution (BIOLOGICAL), BCG Tokyo-172 Strain Solution (BIOLOGICAL), BCG Tokyo-172 Strain Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03091660?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03091660 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Stage 0 Bladder Urothelial Carcinoma
All registered trials for this condition
Stage 0is Bladder Urothelial Carcinoma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.